Thyroid and treatment with Amiodarone Diagnosis, therapy and clinical management;Schilddrüse und Amiodaron-Therapie Diagnostik, therapie und möglichkeiten zum klinischen management

Wiener Medizinische Wochenschrift

Volumn 158, Issue 1-2, 2008, Pages 29-35

  Mikosch, Peter ^a  

^a GENERAL HOSPITAL KLAGENFURT   (Austria)

Author keywords

Amiodarone; Iodine induced hypothyroidism; Iodine induced thyrotoxicosis

Indexed keywords

AMIODARONE; CORTICOSTEROID; LEVOTHYROXINE; LITHIUM; PERCHLORATE; PREDNISOLONE;

ANTIARRHYTHMIC ACTIVITY; DIAGNOSTIC PROCEDURE; DRUG DOSE REDUCTION; HEART ARRHYTHMIA; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; REVIEW; THYROID FUNCTION; THYROIDECTOMY; UNSPECIFIED SIDE EFFECT;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ANTITHYROID AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; IODINE; MALE; PROSPECTIVE STUDIES; RISK FACTORS; THYROID DISEASES; THYROID FUNCTION TESTS; THYROID GLAND; THYROID HORMONES; THYROTOXICOSIS; TIME FACTORS;

EID: 39449124937     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-007-0475-x     Document Type: Review

References (37)

1. Hartong R, Wiersinga WM, Plomp TA (1990) Amiodarone reduces the effect of T3 on beta adrenergic receptor density in rat heart. Horm Metab Res 22: 85-89
2. Basaria S, Cooper DS (2005) Amiodarone and the thyroid. Am J Med 118: 706-714
3. Unger J, Lambert M, Jonckheer MH, Deneyer P (1993) Amiodarone and the thyroid: pharmacological, toxic and therapeutic effects. J Intern Med 233: 435-443
4. Wiersinga WM (1997) Amiodarone and the thyroid. In: Weetman AP, Grossmann A (eds) Handbook of experimental pharmacology, pharmacotherapeutics of the thyroid gland, vol 128. Springer Berlin Heidelberg New York, pp 225-287
5. Perret G, Yin YL, Nikolas P, Pussard E, Vassy R, Uzzan B (1992) Amiodarone decreases cardiac beta-adrenoceptors through an antagonistic effect on 3,5,3′triiodothyronine. J Cardiovasc Pharmacol 19: 473-478
6. Van Beeren HC, Wiersinga WM, Bakker O (1995) Desethylamiodarone is a competitive inhibitor of the binding of the thyroid hormone alpha 1-receptor protein. Mol Cell Endocrinol 112: 15-19
7. Burger A, Dinichert D, Nicod P, Jenny M, Lemarchand-Béraud T, Vallotton MB (1976) Effect of amiodarone on serum triiodothyronine, reverse triiodothyronine, thyroxin, and thyrotropin. A drug influencing peripherial metabolism of thyroid hormones. J Clin Invest 58: 255-259
8. Goedel-Meinen L, Schmidt G, Wirtzfeld A, Jahns G, Klein G, Böttger I, Ulm K, Baedeker W (1984) The effect of amiodarone on thyroid gland function. Z Kardiol 73: 399-404
9. Schroder-van der Elst JP, van der Heide D (1990) Thyroxine, 3,5,3′-triiodothyronine, and 3,3′,5′-triiodothyronine concentrations in several tissues of the rat: effects of amiodarone and desethylamiodarone on thyroid hormone metabolism. Endocrinology 127: 1656-1664
10. Iervasi G, Clerico A, Bonini R, manfredi C, Berti S, Ravani M, Palmieri C, Carpi A, Biagini A, Chopra IJ (1997) Acute effects of amiodarone administration on thyroid function in patients with cardiac arrhythmia. J Clin Endocrinol Metab 82: 275-280
11. Hilleman D, Miller MA, Parker R, Doering P, Pieper JA (1998) Optimal management of amiodarone therapy: efficacy and side effects. Pharmacotherapy 18: 138S-145S
12. Schuetz P, Eriksson U, Christ-Crain M, Zulewski H, Miller B (2005) Amiodarone-induced thyrotoxicosis: a diagnostic and therapeutic challenge. Schweiz Rundsch Med Prax 94: 1397-1401
13. Carle A, Laurberg P, Pedersen IB, Knudsen N, Perrild H, Ovesen L, Rasmussen LB, Jorgensen T (2006) Epidemiology of subtypes of hypothyroidism in Denmark. Eur J Endocrinol 154: 21-28
14. Martino E, Aghini-Lombardi F, Bartalena L, Grasso L, Loviselli A, Velluzzi F, Pinchera A, Braverman LE (1994) Enhanced susceptibility to amiodarone-induced hypothyroidism in patients with thyroid autoimmune disease. Arch Intern Med 154: 2722-2726
15. Martino E, Aghini-Lombardi F, Mariotti S, Bartalena L, Lenziardi M, Ceccarelli C, Bambini G, Safran M, Braverman LE, Pinchera A (1987) Amiodarone iodine-induced hypothyroidism. Risk factors and follow-up in 28 cases. Clin Endocrinol (Oxf) 26: 227-228
16. Trifanescu R, Fica S, Barbu C, Vartej I, Ursu H, Bunghez R, Coculescu M (2004) Amiodarone-induced thyroid dysfunction in cardiac patients from areas with iodine deficiency. Rom J Intern Med 42: 595-605
17. Nakajima K, Yamazaki K, Yamada E, Kanaji Y, Kosaka S, Sato K, Takano K (2001). Amiodarone stimulates interleukin-6 production in cultured human thyrocytes, excerting cytotoxic effects on thyroid follicles in suspension culture. Thyroid 11: 101-109
18. Galvan G (1993) Iodine supply and struma in Austria. Acta Med Austriaca 20: 3-5
19. Gallowitsch HJ, Mikosch P, Kresnik E, Gomez I, Plöb J, Pipam W, Lind P (1994) Thyroid volume and iodine supply of 6 to 17 year old students. Results 3 years after the iintroduction of increased iodized salt. Nuklearmedizin 33: 235-238
20. Heinisch M, Kumnig G, Asböck D, Mikosch P, Gallowitsch HJ, Kresnik E, Gomez I, Unterweger O, Lind P (2002) Goiter prevalence and urinary iodide excretion in a formerly iodine-deficient region after introduction of statutory iodization of common salt. Thyroid 12: 809-814
21. Lind P, Kumnig G, Heinisch M, Igerc I, Mikosch P, Gallowitsch HJ, Kresnik E, Gomez I, Unterweger O, Aigner H (2002. Iodine supplementation in Austria: methods and results. Thyroid 12: 903-907
22. Buchinger W, Lorenz-Wawschinek O, Semlitsch G, Langsteger W, Binter G, Bonelli RM, Eber O (1997) Thyrotropin and thyroglobulin as an index of optimal iodine intake: correlation with iodine excretion of 39,913 euthyroid patients. Thyroid 7: 593-597
23. Simko J, Barta K, Szabo Z, Varga E, Nagy E, Lorincz I (2004) Cardiovascular manifestations of thyrotoxicosis and dysfunction caused by amiodarone. Orv Hetil 145: 2411-2417
24. Alyan O, Arda K, Ozdemir O, Acu B, Soylu M, Demirkan D (2003) Differential diagnosis and clinical course of amiodarone-induced thyroid dysfunction. Med Sci Monit 9: PI117-122
25. Iskander SB, Jordan RM, Peiris AN (20049 Treating amiodarone-induced thyrotoxicosis with radioactive iodine. Tenn Med 97: 408-410
26. Trip MD, Wiersinga W, Plomp TA (1991) Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 91: 507-511
27. Hermida JS, Jarry G, Tcheng E, Moullart V, Arlot S, Rey JL, Schvartz C (2004) Prevention of recurrent amiodarone-induced hyperthyroidism by iodine-131. Arch Mal Coeur Vaiss 97: 207-213
28. Hermida JS, Tcheng E, Jarry G, Moulart V, Arlot S, Rey JL, Delonca J, Schvartz C (2004) Radioiodine ablation of the thyroid to prevent recurrence of amiodarone-induced thyrotoxicosis in patients with resistant tachyarrhythmias. Europace 6: 169-174
29. Bogazzi F, Bartalena L, Tomisti L, Rossi G, Tanda ML, Dell'Unto E, Aghini-Lombardi F, Martino E (2007) Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predictive by thyroid volume and serum free thyroid concentrations. J Clin Endocrinol Metab 92: 556-562
30. Bartalena L, Wiersinga WM, Tanda ML, Bogazzi F, Piantanida E, Lai A, Martino E (2004) Diagnostic and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association. Clin Endocrinol (Oxf) 61: 494-502
31. Dietlein M, Schicha H (2005) Amiodarone-induced thyrotoxicosis due to destructive thyroiditis: therapeutic recommendations. Exp Clin Endocrinol Diabetes 113: 145-151
32. Dickstein G, Shechner C, Adawi F, Kaplan J, Baron E, Ish-Shalom S (1997) Lithium treatment in amiodarone-induced thyrotoxicosis. Am J Med 102: 454-458
33. Houghton SG, MD, Farley DR, Brennan MD, van Heerden JA, Thompson GB, Grant CS (2004) Surgical management of amiodarone-associated thyrotoxicosis: Mayo clinic experience. World J Surg 28: 1083-1087
34. Loberboym M, Schachter P (2007) Drug-induced thyrotoxicosis: the surgical option. Isr Med Assoc J 9: 79-82
35. Burgess C, Blaikie A, Ingham T, Robinson G, Narasimhan S (2006) Monitoring the use of amiodarone: compliance with guidelines. Intern Med J 36: 289-293
36. Bickford CL, Spencer AP (2006) Adherence to the NASPE guideline for amiodarone monitoring at a medical university. J Manag Care Pharm 12: 254-259
37. Siddaway LA (2003) Amiodarone: guidelines for use and monitoring. Am Fam Physician 68: 2189-2196